pentoxifylline has been researched along with Benign Neoplasms in 35 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Based on evidence that suggests pentoxifylline can inhibit tumor necrosis factor, we set out to evaluate the activity and toxicity of this drug in patients with cancer-associated anorexia and/or cachexia." | 9.08 | Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. ( Chong, SF; Ghosh, C; Goldberg, RM; Hestorff, RD; Krook, JE; Loprinzi, CL; Mailliard, JA; O'Fallon, JR; Reuter, NF; Shanahan, TG, 1995) |
| "In this study 30 advanced cancer patients with ARDS were randomized to receive either the conventional care or conventional care plus PTX (100 mg i." | 6.67 | Respiratory distress syndrome in patients with advanced cancer treated with pentoxifylline: a randomized study. ( Ardizzoia, A; Barni, S; Crispino, S; Lissoni, P; Paolorossi, F; Tancini, G; Villa, S, 1993) |
| " It is showed that the use of 100 mg of ladasten, 16 mg of ondansetron orally per day and 50 mg of agomelatine per night is more effective in therapy for fatigue/weakness syndrome in incurable cancer patients compared to standard therapy." | 5.20 | [Optimization of pharmacological therapy for weakness syndrome in incurable patients]. ( Glushchenko, VA; Karitsky, AP; Kvashnin, AV; Rozengard, SA; Ryazankina, AA, 2015) |
| "Based on evidence that suggests pentoxifylline can inhibit tumor necrosis factor, we set out to evaluate the activity and toxicity of this drug in patients with cancer-associated anorexia and/or cachexia." | 5.08 | Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. ( Chong, SF; Ghosh, C; Goldberg, RM; Hestorff, RD; Krook, JE; Loprinzi, CL; Mailliard, JA; O'Fallon, JR; Reuter, NF; Shanahan, TG, 1995) |
| "Pentoxifylline (PTX) is a vasoactive synthetic methyl xanthine derivative used for decades to manage chronic occlusive vascular disorders." | 3.01 | Parsimonious Effect of Pentoxifylline on Angiogenesis: A Novel Pentoxifylline-Biased Adenosine G Protein-Coupled Receptor Signaling Platform. ( Baghaie, L; Chen, X; Clark, M; El-Diasty, M; Khoury, W; Szewczuk, MR; Trus, R, 2023) |
| "In this study 30 advanced cancer patients with ARDS were randomized to receive either the conventional care or conventional care plus PTX (100 mg i." | 2.67 | Respiratory distress syndrome in patients with advanced cancer treated with pentoxifylline: a randomized study. ( Ardizzoia, A; Barni, S; Crispino, S; Lissoni, P; Paolorossi, F; Tancini, G; Villa, S, 1993) |
| "Studies have recruited heterogeneous cancer patient populations in late disease stages, and many had issues with accrual and attrition." | 2.61 | Anti-cytokines in the treatment of cancer cachexia. ( Prado, BL; Qian, Y, 2019) |
| "Pentoxifylline (PTX) is a drug commonly used in the treatment of intermittent claudication." | 2.58 | Potential Use of Pentoxifylline in Cancer Therapy. ( Golunski, G; Piosik, J; Woziwodzka, A, 2018) |
| "Regarding radiosensitization of tumors, a large body of evidence suggests that Ptx improves tumor oxygenation and sensitizes p53 mutant tumors." | 2.43 | The role of pentoxifylline as a modifier of radiation therapy. ( Adam, M; Molls, M; Nieder, C; Zimmermann, FB, 2005) |
| " In general, the dose-response characteristics were strikingly biphasic in nature and were independent of both the target tissue and chemoattractant agent." | 2.41 | Cell migration/chemotaxis: biphasic dose responses. ( Calabrese, EJ, 2001) |
| "Telmisartan-treated tumours were more responsive to radiation, indicating that telmisartan reduces a therapeutically important population of transiently hypoxic tumour cells." | 1.56 | Angiotensin II type 1 receptor blocker telmisartan inhibits the development of transient hypoxia and improves tumour response to radiation. ( Benard, F; Bennewith, KL; Cederberg, RA; Colpo, N; Firmino, NS; Franks, SE; Lee, CM; Lin, KS; Pan, J; Wadsworth, BJ, 2020) |
| " Consistent additive to synergistic interactions were observed in HCT116 cells when PENT was combined with SAHA at all drug tested concentrations." | 1.46 | Enhanced anticancer efficacy of histone deacetyl inhibitor, suberoylanilide hydroxamic acid, in combination with a phosphodiesterase inhibitor, pentoxifylline, in human cancer cell lines and in-vivo tumor xenografts. ( Chandrasekhar, KB; Karthikeyan, K; Khan, FR; Kulkarni, NM; Narayanan, S; Nidhyanandan, S; Raghul, J; Reddy, ND; Thippeswamy, BS; Vijaykanth, G, 2017) |
| "Aim in cancer therapy is to increase the therapeutic ratio eliminating the disease while minimizing toxicity to normal tissues." | 1.34 | Induced and repressed genes after irradiation sensitizing by pentoxyphylline. ( Braun, K; Debus, J; Didinger, B; Hotz-Wagenblatt, A; Langowski, J; Müller, G; Strunz, AM; Waldeck, W; Wijenne, J, 2007) |
| "Pentoxifylline did not suppress TNF RNA to subnormal levels in all five patients with initially normal TNF RNA levels." | 1.29 | Down-regulation of tumor necrosis factor expression by pentoxifylline in cancer patients: a pilot study. ( Allen-Ryan, J; Dezube, BJ; Fridovich-Keil, JL; Pardee, AB; Sherman, ML, 1993) |
| "Pentoxifylline was added after incubation of normal cells with patient serum, and the directed chemotaxis was restored." | 1.28 | Pentoxifylline in vitro reverses neutrophil chemotactic deficiency induced by interleukin-2 treatment. ( Fossat, C; Juhan-Vague, I; Maraninchi, D; Sainty, D; Stoppa, AM, 1992) |
| " This regimen can be safely administered on an outpatient basis, with adequate control of gastrointestinal symptoms achieved by standard antiemetics and intermittent dosing with meals." | 1.28 | Phase I trial of escalating pentoxifylline dose with constant dose thiotepa. ( Dezube, BJ; Eder, JP; Pardee, AB, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (5.71) | 18.7374 |
| 1990's | 10 (28.57) | 18.2507 |
| 2000's | 10 (28.57) | 29.6817 |
| 2010's | 7 (20.00) | 24.3611 |
| 2020's | 6 (17.14) | 2.80 |
| Authors | Studies |
|---|---|
| Diamandis, P | 1 |
| Wildenhain, J | 1 |
| Clarke, ID | 1 |
| Sacher, AG | 1 |
| Graham, J | 1 |
| Bellows, DS | 1 |
| Ling, EK | 1 |
| Ward, RJ | 1 |
| Jamieson, LG | 1 |
| Tyers, M | 1 |
| Dirks, PB | 1 |
| Lin, R | 1 |
| Elf, S | 1 |
| Shan, C | 1 |
| Kang, HB | 1 |
| Ji, Q | 1 |
| Zhou, L | 1 |
| Hitosugi, T | 1 |
| Zhang, L | 1 |
| Zhang, S | 1 |
| Seo, JH | 1 |
| Xie, J | 1 |
| Tucker, M | 1 |
| Gu, TL | 1 |
| Sudderth, J | 1 |
| Jiang, L | 1 |
| Mitsche, M | 1 |
| DeBerardinis, RJ | 1 |
| Wu, S | 1 |
| Li, Y | 1 |
| Mao, H | 1 |
| Chen, PR | 1 |
| Wang, D | 1 |
| Chen, GZ | 1 |
| Hurwitz, SJ | 1 |
| Lonial, S | 1 |
| Arellano, ML | 1 |
| Khoury, HJ | 1 |
| Khuri, FR | 1 |
| Lee, BH | 1 |
| Lei, Q | 1 |
| Brat, DJ | 1 |
| Ye, K | 1 |
| Boggon, TJ | 1 |
| He, C | 1 |
| Kang, S | 1 |
| Fan, J | 1 |
| Chen, J | 1 |
| Joshi, TP | 1 |
| Duvic, M | 1 |
| Khoury, W | 1 |
| Trus, R | 1 |
| Chen, X | 1 |
| Baghaie, L | 1 |
| Clark, M | 1 |
| Szewczuk, MR | 1 |
| El-Diasty, M | 1 |
| Altundag, K | 1 |
| Larocca, CA | 1 |
| Fay, CJ | 1 |
| Hirner, JP | 1 |
| Meyerhardt, JA | 1 |
| Cleary, JM | 1 |
| Dewan, AK | 1 |
| LeBoeuf, NR | 1 |
| Betzler, AC | 1 |
| Theodoraki, MN | 1 |
| Schuler, PJ | 1 |
| Döscher, J | 1 |
| Laban, S | 1 |
| Hoffmann, TK | 1 |
| Brunner, C | 1 |
| Wadsworth, BJ | 1 |
| Cederberg, RA | 1 |
| Lee, CM | 1 |
| Firmino, NS | 1 |
| Franks, SE | 1 |
| Pan, J | 1 |
| Colpo, N | 1 |
| Lin, KS | 1 |
| Benard, F | 1 |
| Bennewith, KL | 2 |
| Nidhyanandan, S | 1 |
| Thippeswamy, BS | 1 |
| Chandrasekhar, KB | 1 |
| Reddy, ND | 1 |
| Kulkarni, NM | 1 |
| Karthikeyan, K | 1 |
| Khan, FR | 1 |
| Raghul, J | 1 |
| Vijaykanth, G | 1 |
| Narayanan, S | 1 |
| Golunski, G | 1 |
| Woziwodzka, A | 1 |
| Piosik, J | 1 |
| Prado, BL | 1 |
| Qian, Y | 1 |
| Amber, KT | 1 |
| Shiman, MI | 1 |
| Badiavas, EV | 1 |
| Neo, WH | 1 |
| Lim, JF | 1 |
| Grumont, R | 1 |
| Gerondakis, S | 1 |
| Su, IH | 1 |
| Ryazankina, AA | 1 |
| Rozengard, SA | 1 |
| Glushchenko, VA | 1 |
| Karitsky, AP | 1 |
| Kvashnin, AV | 1 |
| Hanly, AM | 1 |
| Hayanga, A | 1 |
| Winter, DC | 1 |
| Bouchier-Hayes, DJ | 1 |
| Argilés, JM | 1 |
| Busquets, S | 1 |
| López-Soriano, FJ | 1 |
| Nieder, C | 1 |
| Zimmermann, FB | 1 |
| Adam, M | 1 |
| Molls, M | 1 |
| Waldeck, W | 1 |
| Strunz, AM | 1 |
| Müller, G | 1 |
| Hotz-Wagenblatt, A | 1 |
| Wijenne, J | 1 |
| Langowski, J | 1 |
| Didinger, B | 1 |
| Debus, J | 1 |
| Braun, K | 1 |
| Gastpar, H | 2 |
| Ambrus, JL | 3 |
| Ambrus, CM | 3 |
| Blume, E | 1 |
| Goldberg, RM | 1 |
| Loprinzi, CL | 1 |
| Mailliard, JA | 1 |
| O'Fallon, JR | 1 |
| Krook, JE | 1 |
| Ghosh, C | 1 |
| Hestorff, RD | 1 |
| Chong, SF | 1 |
| Reuter, NF | 1 |
| Shanahan, TG | 1 |
| Dezube, BJ | 2 |
| Sherman, ML | 1 |
| Fridovich-Keil, JL | 1 |
| Allen-Ryan, J | 1 |
| Pardee, AB | 2 |
| Balázs, C | 1 |
| Kiss, E | 1 |
| Ardizzoia, A | 1 |
| Lissoni, P | 1 |
| Tancini, G | 1 |
| Paolorossi, F | 1 |
| Crispino, S | 1 |
| Villa, S | 1 |
| Barni, S | 1 |
| Honess, DJ | 1 |
| Kitamoto, Y | 1 |
| Rampling, MR | 1 |
| Bleehen, NM | 1 |
| Calabrese, EJ | 1 |
| Burks, TF | 1 |
| Sarkaria, JN | 1 |
| Eshleman, JS | 1 |
| Durand, RE | 1 |
| Sibtain, A | 1 |
| Hill, S | 1 |
| Goodchild, K | 1 |
| Shah, N | 1 |
| Saunders, M | 1 |
| Hoskin, PJ | 1 |
| Fossat, C | 1 |
| Sainty, D | 1 |
| Stoppa, AM | 1 |
| Maraninchi, D | 1 |
| Juhan-Vague, I | 1 |
| Tuckey, JA | 1 |
| Parry, BR | 1 |
| McCall, JL | 1 |
| Toumbis, CA | 1 |
| Forgach, P | 1 |
| Karakousis, CP | 1 |
| Niswander, P | 1 |
| Lane, W | 1 |
| Eder, JP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer[NCT06115174] | Phase 4 | 44 participants (Anticipated) | Interventional | 2023-11-01 | Not yet recruiting | ||
| Nabilone Effect on the Attenuation of Anorexia, Nutritional Status and Quality of Life in Patients With Anorexia Associated With Advanced Lung Cancer: Randomized Double Blind Clinical Trial[NCT02802540] | Phase 2/Phase 3 | 78 participants (Anticipated) | Interventional | 2014-12-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
15 reviews available for pentoxifylline and Benign Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
Granuloma Annulare: An Updated Review of Epidemiology, Pathogenesis, and Treatment Options.
Topics: Anti-Infective Agents; Antimalarials; Biological Therapy; Comorbidity; Dermatologic Agents; Diabetes | 2022 |
Parsimonious Effect of Pentoxifylline on Angiogenesis: A Novel Pentoxifylline-Biased Adenosine G Protein-Coupled Receptor Signaling Platform.
Topics: Adenosine; Animals; Humans; Neoplasms; Pentoxifylline | 2023 |
NF-κB and Its Role in Checkpoint Control.
Topics: Animals; B7-H1 Antigen; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Cyclooxygenase 2; Cyclooxygenas | 2020 |
Potential Use of Pentoxifylline in Cancer Therapy.
Topics: Animals; Antineoplastic Agents; Humans; Neoplasms; Pentoxifylline | 2018 |
Anti-cytokines in the treatment of cancer cachexia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cachexia; Cytokines; Etanercept; Forecast | 2019 |
The use of antioxidants in radiotherapy-induced skin toxicity.
Topics: Antioxidants; Ascorbic Acid; Free Radical Scavengers; Humans; Neoplasms; Pentoxifylline; Polyphenols | 2014 |
Thrombomodulin: tumour biology and prognostic implications.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Down-Regulation; Gene Expression Regulatio | 2005 |
The pivotal role of cytokines in muscle wasting during cancer.
Topics: Animals; Anorexia; Antibodies; Cachexia; Cytokines; Humans; Models, Biological; Muscle, Skeletal; Mu | 2005 |
The role of pentoxifylline as a modifier of radiation therapy.
Topics: Animals; Clinical Trials as Topic; Combined Modality Therapy; Humans; Neoplasms; Pentoxifylline; Rad | 2005 |
Immunological aspects of the effect of pentoxifylline (Trental) (a brief review).
Topics: Animals; Cytokines; HIV Infections; Humans; Immune System; In Vitro Techniques; Neoplasms; Pentoxify | 1994 |
Cell migration/chemotaxis: biphasic dose responses.
Topics: Alcohols; alpha 1-Antitrypsin; Animals; Cell Movement; Chemotaxis; Dose-Response Relationship, Drug; | 2001 |
New agents for the treatment of cancer-related fatigue.
Topics: alpha-MSH; Anti-Inflammatory Agents, Non-Steroidal; Bradykinin; Cyclooxygenase 1; Cyclooxygenase 2; | 2001 |
ATM as a target for novel radiosensitizers.
Topics: Ataxia Telangiectasia; Ataxia Telangiectasia Mutated Proteins; Caffeine; Cell Cycle; Cell Cycle Prot | 2001 |
Methylxanthines in surgery: a bright future?
Topics: Humans; Neoplasms; Pentoxifylline; Respiratory Distress Syndrome; Shock, Septic; Surgical Procedures | 1992 |
3 trials available for pentoxifylline and Benign Neoplasms
| Article | Year |
|---|---|
[Optimization of pharmacological therapy for weakness syndrome in incurable patients].
Topics: Acetamides; Adamantane; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Ant | 2015 |
Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial.
Topics: Aged; Anorexia; Appetite; Body Weight; Cachexia; Double-Blind Method; Female; Humans; Male; Middle A | 1995 |
Respiratory distress syndrome in patients with advanced cancer treated with pentoxifylline: a randomized study.
Topics: Administration, Oral; Adult; Aged; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neopla | 1993 |
17 other studies available for pentoxifylline and Benign Neoplasms
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutic | 2007 |
The use of pentoxifylline might enhance the effect of chemotherapy or radiotherapy in reducing tumor growth.
Topics: Humans; Lymphocytes, Tumor-Infiltrating; Neoplasms; Pentoxifylline; Radiation Oncology; Vitamin E | 2023 |
Diffuse Cutaneous Aphthosis After Combined Targeted Cancer Therapies and Responsive to Pentoxifylline.
Topics: Behcet Syndrome; Humans; Neoplasms; Pentoxifylline; Skin; Stomatitis, Aphthous | 2023 |
Angiotensin II type 1 receptor blocker telmisartan inhibits the development of transient hypoxia and improves tumour response to radiation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cancer-Associated Fibroblasts; Cell Line, Tumor; C | 2020 |
Enhanced anticancer efficacy of histone deacetyl inhibitor, suberoylanilide hydroxamic acid, in combination with a phosphodiesterase inhibitor, pentoxifylline, in human cancer cell lines and in-vivo tumor xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Growth Processe | 2017 |
c-Rel regulates Ezh2 expression in activated lymphocytes and malignant lymphoid cells.
Topics: Animals; Base Sequence; Cell Line, Tumor; Cell Nucleus; Cell Survival; Enhancer of Zeste Homolog 2 P | 2014 |
Induced and repressed genes after irradiation sensitizing by pentoxyphylline.
Topics: Cell Line, Tumor; Down-Regulation; Gene Expression; Gene Expression Profiling; Genome, Human; Humans | 2007 |
Platelet cancer cell interaction in metastasis formation. Platelet aggregation inhibitors: a possible approach to metastasis prevention.
Topics: Animals; Bencyclane; Blood Platelet Disorders; Blood Platelets; Carcinoma 256, Walker; Cell Adhesion | 1982 |
Platelet aggregation inhibitors and metastatic spread of neoplastic cells.
Topics: Animals; Blood Platelets; Female; Humans; Male; Mice; Mopidamol; Neoplasm Metastasis; Neoplasm Trans | 1982 |
Researchers gain footholds in the cell cycle.
Topics: Alkaloids; Animals; Antineoplastic Agents; Cell Cycle; DNA, Neoplasm; Humans; Neoplasms; Pentoxifyll | 1995 |
Down-regulation of tumor necrosis factor expression by pentoxifylline in cancer patients: a pilot study.
Topics: Adult; Cachexia; Humans; Neoplasms; Pentoxifylline; Pilot Projects; RNA; Tumor Necrosis Factor-alpha | 1993 |
Nicotinamide and pentoxifylline increase human leucocyte filterability: a possible mechanism for reduction of acute hypoxia.
Topics: Cell Hypoxia; Dose-Response Relationship, Drug; Filtration; Humans; Leukocytes; Neoplasms; Niacinami | 1996 |
Drug-induced alterations in tumour perfusion yield increases in tumour cell radiosensitivity.
Topics: Animals; Calcium Channel Blockers; Diltiazem; Dose-Response Relationship, Drug; Flow Cytometry; Hema | 2001 |
The modification of human tumour blood flow using pentoxifylline, nicotinamide and carbogen.
Topics: Administration, Inhalation; Administration, Oral; Adult; Aged; Carbon Dioxide; Female; Humans; Laser | 2002 |
Pentoxifylline in vitro reverses neutrophil chemotactic deficiency induced by interleukin-2 treatment.
Topics: Bacteremia; Bone Marrow Transplantation; Cells, Cultured; Chemotaxis, Leukocyte; Disease Susceptibil | 1992 |
Studies on tumor induced angiogenesis.
Topics: Animals; Cornea; Ditiocarb; Humans; Macaca; Neoplasms; Neovascularization, Pathologic; Pentoxifyllin | 1991 |
Phase I trial of escalating pentoxifylline dose with constant dose thiotepa.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug | 1990 |